Cancer, Locally Advanced Pancreatic Cancer, Non-invasive Treatment, Pancreas
Conditions
Keywords
Locally advanced Pancreatic Cancer, Noninvasive treatment, High Intensity focused ultrasound, Magnetic Resonance
Brief summary
Patients with unresectable pancreatic cancer in most of cases cannot benefit from percutaneous ablation modalities, due to high risk of procedure-related complications. Ultrasound-guided high intensity focused ultrasound (HIFU) ablation has been introduced as a feasible treatment option in these patients. However, in other anatomical regions US-guided HIFU has been replaced by the more accurate MR-guided focused ultrasound (MRgFUS) ablation, but the applicability of this latter technique to the treatment of pancreatic cancer is still unexplored. The aim of this study is to explore feasibility and clinical performance of MRgFUS ablation of unresectable pancreatic cancer. Two are the main end-points: Pain palliation and local tumor control. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate, non-invasive ablation modality even for unresectable pancreatic cancer although, to date, no cases of pancreatic MRgFUS ablation have been reported.
Interventions
PROCEDUREMagnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)
High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
Sponsors
University of Roma La Sapienza
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Inclusion criteria
* biopsy proven unresectable pancreatic adenocarcinoma; * unable or not willing to undergo chemo-radiation therapy * Celiac plexus alcoholization failed to control pain symptoms
Exclusion criteria
* contraindication to MR or general anesthesia
Countries
Italy
Contacts
Primary Contactalessandro napoli, MD, PhD
Outcome results
None listed